MentionFox
Home › Executive changes › Alaunos Therapeutics, Inc.
Leadership changes · TCRT · SEC Form 8-K, Item 5.02

Leadership changes at Alaunos Therapeutics, Inc. (2026)

Alaunos Therapeutics, Inc. (TCRT) leadership changes: 1 appointment reported on 2026-10-13. Who came in, who left and in what role, each cited to the company's own filing.

Sell to companies like these? Paste your website and see 10 with a filed reason to buy this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-10-13

Alaunos Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-13. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Alaunos Therapeutics, Inc. files it.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-10-13InPeter HarwinDirector8-K, 2026-10-13

Selling to them or working with them? See who runs Alaunos Therapeutics, Inc. now and the warning signs.

Watch Alaunos Therapeutics, Inc.

Free to see. No signup.

Want the whole picture on Alaunos Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Alaunos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Alaunos Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on Target: the verdict, 16 sections, 39 cited sources, dated 2026-09-28A real finished report, first screen. Opens in a new tab.

Leadership as last reported

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Alaunos Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Alaunos Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Alaunos Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Director at Alaunos Therapeutics, Inc., with the record behind each one.

Find candidates like Director at Alaunos Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-10-13 · 8-K

Appointed: Peter Harwin, Director

Appointment of Directors In accordance with the Merger Agreement, on October 13, 2026, effective immediately after the effective time of the Second Merger, Peter Harwin was appointed to the Board as a director.

Tools for this story

Each opens in a new tab, filled in for Alaunos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/alaunos-therapeutics
Last updated 2026-10-18
Primary record: SEC filing
Leadership changes at Alaunos Therapeutics, Inc. (2026). MentionFox, 2026-10-18. https://mentionfox.com/executive-changes/alaunos-therapeutics